BELLUS Health Inc. (BLU) Hourly Stock Prediction • Stock Signals Live

You do not have permission to access this chart.

Please Sign Up or Login

Login Here | Not a member? Join Now

News for BELLUS Health Inc. (BLU)

Newly released Crypto mining rig for BELLUS Health Inc. coins

minutes ago | Banggood.com

Everything Crypto on sale now!

58 minutes ago | Aliexpress.com

BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights

3 days ago | Business Wire

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference

2 months ago | Business Wire

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

3 months ago | Newsfile Corp

BLU Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU

3 months ago | Newsfile Corp

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU

3 months ago | Newsfile Corp

Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.

3 months ago | Business Wire

BLU LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BELLUS Health Inc.

3 months ago | Newsfile Corp

BLU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 17, 2021 in the Class Action Filed on Behalf of BELLUS Health Inc. Limited Shareholders

3 months ago | Newsfile Corp

BLU FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action - BLU

3 months ago | Newsfile Corp

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

3 months ago | Newsfile Corp

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

32

Address:

BELLUS Health Inc. 275 Armand-Frappier Boulevard Laval QC H7V 4A7 Canada

Website:

Home

Phone:

450-680-4500

Leave a comment

Cancel reply